Results 191 to 200 of about 3,492,883 (216)

High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer

Lung Cancer, 2011
Prior studies highlighted cyclin D1 as a key biomarker of response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. This study builds on prior work by examining the roles of cyclin D1, cyclin D3, and cyclin E in mediating erlotinib sensitivity or resistance.Expression plasmids for G1 cyclins were independently transfected into NIH
Petty, W., Voelzke, W., Urbanic, J., Varela, V., Waller, L., Swift, C., Graham, Ross, Memoli, V., Dragnev, K.   +8 more
openaire   +3 more sources

Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours

Lung Cancer, 2008
For patients with advanced non-small cell lung cancer (NSCLC), the introduction of the epi- dermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, into clinical practice was promising. Treatment with either of these agents is associated with an objective response in 10-20% of patients.
openaire   +2 more sources

Synthesis and biological evaluation of novel pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines

Bioorganic & Medicinal Chemistry Letters, 2013
A series of novel pyrido[2,3-b]pyrazines were synthesized as potential antitumor agents for erlotinib-resistant tumors. Known signal inhibitor compounds from our Nested Chemical Library were tested in phenotypic assays on erlotinib-sensitive PC9 and erlotinib-resistant PC9-ER cell lines to find a compound class to be active on erlotinib resistant cell ...
Kékesi, László, Sipos, Anna, Németh, Gábor, Pato J,, Breza N,, Baska, Ferenc, Őrfi, László, Kéri, György   +7 more
openaire   +3 more sources

Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells

AAPS PharmSciTech, 2019
Lung cancer patients develop acquired resistance to tyrosine kinase inhibitors including erlotinib (ERL) after few months of primary treatment. Evidently, new chemotherapy strategies to delay or overcome the resistance are urgently needed to improve the clinical outcome in non-small cell lung cancer (NSCLC) patients. In this paper, we have investigated
Ketan, Patel, Ravi, Doddapaneni, Manali, Patki, Vasanthkumar, Sekar, Arvind, Bagde, Mandip, Singh   +5 more
openaire   +2 more sources

Phase II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.

Journal of Clinical Oncology, 2010
7557 Background: The most common mechanism of acquired resistance to erlotinib (initial response followed by progressive disease) is development of a secondary mutation in the epidermal growth fact...
G. J. Riely, Y. Y. Janjigian, C. G. Azzoli, M. Pietanza, L. M. Krug, N. A. Rizvi, M. G. Kris, V. A. Miller, W. Pao, M. S. Ginsberg   +9 more
openaire   +1 more source

Abstract A263: Combination of quinacrine and erlotinib overcomes resistance to erlotinib in non-small cell lung cancer.

Molecular Cancer Therapeutics, 2013
Abstract The epidermal growth factor receptor (EGFR) inhibitor erlotinib is highly effective in non-small cell lung cancer (NSCLC) patients whose tumors express EGFR mutations, e.g., EGFR-L858R or EGFR exon 19 del. However, the efficacy of erlotinib is limited by either primary or secondary resistance, i.e., in patients whose tumors ...
Josephine Kam Tai Dermawan, Katerina Gurova, John Pink, Afshin Dowlati, Sarmishtha De, Goutham Narla, Neelesh Sharma, George Stark   +7 more
openaire   +1 more source

Abstract 760: On the evolution of erlotinib-resistant NSCLC subpopulations

Cancer Research, 2015
Abstract One of the foremost challenges to cancer treatment is the emergence of drug resistance. Adding complexity to this problem is the recent realization that drug resistance can stem from selection for both intrinsically resistant subpopulations as well as subpopulations that adapt to the drug challenge through epigenetic and/or ...
Michael E. Ramirez, Robert J. Steininger, Lani F. Wu, Steven J. Altschuler   +3 more
openaire   +1 more source

Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer

Lung Cancer, 2007
Failure to gefitinib is generally believed to be associated with cross-resistance to other epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). Here we report a case whose active EGFR-mutant NSCLC responded to erlotinib treatment.Lung specimen was obtained during diagnostic procedures from a 41-year-old Taiwanese male smoker with ...
John Wen-Cheng, Chang, Chun-Liang, Chou, Shiu-Feng, Huang, Hung-Ming, Wang, Jia-Juan, Hsieh, Todd, Hsu, Yun-Chung, Cheung   +6 more
openaire   +2 more sources

Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer

Science Signaling, 2015
Triple antibody targeting of multiple receptors subverts the resistance induced by single-agent therapies in lung cancer.
M. Mancini, N. Gaborit, M. Lindzen, T. Meir Salame, M. Dall'Ora, M. Sevilla-Sharon, A. Abdul-Hai, J. Downward, Y. Yarden   +8 more
openaire   +2 more sources

Non-invasive detection of EGFR T790M in gefitinib/erlotinib resistant NSCLC

Journal of Clinical Oncology, 2008
8075 Background: Fifty percent of NSCLC patients (pts) that develop a partial (PR) or complete (CR) response to gefitinib (G) or erlotinib (E) will develop a secondary EGFR T790M mutation as a mech...
Y. Kuang, A. Rogers, L. Wang, M. Makrigiorgos, K. Vetrand, S. Thiede, R. Distel, P. A. Janne   +7 more
openaire   +1 more source